Published in AIDS Weekly, May 17th, 1999
Monkeys primed with intradermal HIV DNA and boosted with recombinant fowlpox virus (rFPV)-expressed HIV protein developed very low-level infections but remained disease free after challenge with pathogenic SHIV (chimeric virus with an HIV coat over an SIV backbone). Deployment of such a vaccine in areas with a high incidence of infection would be expected to greatly reduce HIV transmission as well as AIDS morbidity and mortality.
"The ability to achieve stringent containment of serial SHIV challenges using intradermal DNA priming and recombinant...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.